Bioavailability / Bioequivalence, Dissolution and Biowaivers 2014 is a conference that covers topics such as:
- Key similarities and differences between the EMA and FDA Bioanalytical Method Validation guidances
- Updates on the new EMA Modified Release Guidance read more
- Case study on BE studies for fixed dose combination products
- The advantages and complexities of the EMA Bioequivalence Concept Paper
- 4 new dissolution testing case studies from GSK, NextPharma, Eli Lilly and Bayer, including
- Strategic advice and practical insight on highly variable drugs
- Industry use and experiences on bio-relevant dissolution testing
Bioavailability / Bioequivalence, Dissolution and Biowaivers 2014 brings together heads, Directors, scientists, managers and specialists from:
- Analytical development
- Pre-clinical & clinical development
- Quality control
- Research and development
- Pharmacokinetics
- Clinical pharmacology
- Medical Affairs
- Regulatory affairs
